VOLUME LXXIV | FEB 2023

Unlocking the Potential of Antidiabetic Medication for Alzheimer’s Disease

Dr. David Lowemann
Dr. David Lowemann, M.Sc, Ph.D., is a co-founder of the Institute for the Future of Human Potential, where he leads the charge in pioneering

Imagine you have a toolbox full of different tools, but you’re not sure which one will fix a particular problem. That’s the situation we’re facing when it comes to finding a treatment for Alzheimer’s disease (AD). Researchers have discovered that there is a connection between type 2 diabetes and AD, with diabetes increasing the risk of developing AD. This has led scientists to explore the use of clinical antidiabetic medication as a potential therapy for AD. However, while these medications show promise in basic research, their effectiveness in clinical trials has been limited. In this review, researchers discuss the opportunities and challenges that arise when translating antidiabetic medication from basic discovery to therapeutic development for AD. By understanding the progress made so far, we can offer hope to patients with specific types of AD caused by high blood glucose levels or insulin resistance. If you’re curious about this exciting field of research, dive into the full article to learn more!

Alzheimer’s disease (AD) is a common neurodegenerative disease. Type 2 diabetes mellitus (T2DM) appears to increase and contributing to the risk of AD. Therefore, there is increasing concern about clinical antidiabetic medication used in AD. Most of them show some potential in basic research, but not in clinical research. So we reviewed the opportunities and challenges faced by some antidiabetic medication used in AD from basic to clinical research. Based on existing research progress, this is still the hope of some patients with special types of AD caused by rising blood glucose or/and insulin resistance.

Read Full Article (External Site)